Key facts: ChrysCapital acquires stake in Novartis India; Remibrutinib trials positive; US expansion planned
I'm PortAI, I can summarize articles.
ChrysCapital has secured a majority stake in Novartis India, including standard warranties and a commitment to support the mandatory open offer to public shareholders as per SEBI rules.1Novartis AG announced positive results from a phase 3 trial of Remibrutinib for chronic inducible urticaria, showing higher response rates than placebo at Week 12, meeting primary endpoints.2Novartis is expanding in the US with new manufacturing and research facilities in North Carolina and California, plus a radioligand therapy site in Florida, following a major investment.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments